Caring for patients with pain during the COVID-19 pandemic: Consensus recommendations from an international expert panel

H. Shanthanna, N. H. Strand, D. A. Provenzano, C. A. Lobo, S. Eldabe, A. Bhatia, J. Wegener, K. Curtis, S. P. Cohen, S. Narouze

1 Associate Professor, Department of Anesthesia, McMaster University, ON, Canada
2 Assistant Professor, Division of Pain Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ, USA
3 President, Pain Diagnostics and Interventional Care, Sewickley, PA, USA
4 Consultant, Department of Anaesthesiology, Hospital das Forças Armadas, Pólo Porto, Portugal
5 Professor, Department of Pain Medicine, The James Cook University Hospital, Middlesbrough, UK
6 Associate Professor and Staff, Comprehensive Integrated Pain Program-Interventional Pain Service, Department of Anesthesia and Pain Medicine, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
7 Consultant, Department of Anesthesiology, Sint Maartenskliniek, Nijmegen, The Netherlands
8 Clinical Psychologist, Comprehensive Integrated Pain Program-Interventional Pain Service, Department of Anesthesia and Pain Medicine, Toronto Western Hospital, Toronto, ON, Canada
9 Professor, Department of Anesthesiology and Critical Care Medicine, Neurology and Physical Medicine and Rehabilitation, Johns Hopkins School of Medicine, Baltimore, MD, USA
10 Professor, Northeast Ohio Medical University and Chairman, Center for Pain Medicine, Western Reserve Hospital, OH, USA

Correspondence to: H. Shanthanna
Email: shanthh@mcmaster.ca

Keywords: chronic pain; COVID-19; opioids; recommendations; steroids

Twitter: @harshamd5; @claralexlobo; @NarouzeMD

Short title: Consensus Recommendations on Caring for Pain Patients during COVID-19

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ANAE.15076

This article is protected by copyright. All rights reserved
Summary

Chronic pain causes significant suffering, limitation of daily activities and reduced quality of life. Infection from COVID-19 is responsible for an ongoing pandemic that causes severe acute respiratory syndrome, leading to systemic complications and death. Led by the World Health Organization, healthcare systems across the world are engaged in limiting the spread of infection. As a result all elective surgeries, procedures, and patient visits, including pain management services, have been postponed or cancelled. This has impacted the care of chronic pain patients. Most are elderly with multiple comorbidities, which puts them at risk of COVID-19 infection. Important considerations that need to be recognised during this pandemic for chronic pain patients include: ensuring continuity of care and pain medications, especially opioids; use of telemedicine; maintaining biopsychosocial management; use of anti-inflammatory drugs; use of steroids; and prioritising necessary procedural visits. There are no guidelines to inform physicians and healthcare providers engaged in caring for patients with pain during this period of crisis. We assembled an expert panel of pain physicians, psychologists and researchers from North America and Europe to formulate recommendations to guide practice. As the COVID-19 situation continues to evolve rapidly, these recommendations are based on the best available evidence and expert opinion at this present time and may need adapting to local workplace policies.

Introduction

Chronic pain is a prevalent condition worldwide and causes suffering, limitation of daily activities and reduced quality of life [1-3]. According to the United States 2012 National Health Interview Survey, 126.1 million adults reported some pain in the previous 3 months, with 25.3 million adults (11.2%) suffering from daily chronic pain and 14.4 million (6.3%) reporting “a lot” of pain most days or every day [4]. In Europe, almost one in five individuals report having moderate or severe chronic pain, and in the UK the prevalence of moderate to severely disabling chronic pain is estimated to range between 10.4% and 14.3% [5,6]. Most chronic pain conditions occur in the elderly and are musculoskeletal in nature, such as low back, neck and joint pain. These contribute to the largest number of years lived with disability [7, 8]. In the UK, over 50% of the elderly population reported that chronic pain was the most important factor affecting their quality of life [9]. Chronic pain patients often suffer with co-existing...
comorbidities [5, 6]. In a large cross-sectional database study involving 1,751,841 people, pain was the most common co-existing condition among four common disease states: coronary artery disease; diabetes; cancer; and chronic obstructive pulmonary disease [10]. Adequate management of chronic pain is not only a moral and ethical imperative, but also mitigates against subsequent physical and psychological complications [7, 11, 12].

Novel COVID-19 infection can cause severe acute respiratory syndrome (SARS) and death. It is responsible for the ongoing pandemic and on 1 April 2020 there were 883,225 confirmed cases with 44,156 deaths globally (https://coronavirus.jhu.edu/map.html). Healthcare systems across the world have been faced with the challenge of controlling the infection. This has encompassed decisions such as postponing or cancelling all elective surgery procedures and patient visits, including suspension of many pain management services. The care of chronic pain patients has been significantly impacted. Many of these patients have complex needs and urgently require interventions to stave off potentially life-threatening conditions or are facing opioid withdrawal [13, 14].

We performed a literature search that did not identify any document or guidelines for the management of chronic pain patients, either during the current crisis or at the time of previous epidemic or pandemic outbreaks, including SARS-2003. In response to the urgent need, an expert panel consisting of healthcare providers and pain researchers from North America and Europe were brought together to formulate practice recommendations to help physicians and health providers continue to care for their chronic pain patients [15].

**Methods**

The first and senior authors (HS, SN) identified and invited physicians and psychologists to participate in the expert panel for framing these recommendations. All panel members were engaged in caring for patients with chronic pain, had experience and training in clinical research, and had previously participated in the formulation of guideline statements and practice recommendations. We conducted a systematic search of the Medline database for terms referring to ‘COVID-19’ [*Coronavirus Infections/ or *SARS Virus/ or SARS.mp. or *Coronavirus/ or *Severe Acute Respiratory Syndrome/COVID-19] and ‘chronic pain/pain’ to inform this process. Based on the present pathophysiological understanding of COVID-19 and potential practice implications based on either the ‘pathology’ or ‘nature of chronic pain treatment’, the panel developed themes upon which to formulate our practice recommendations.

This article is protected by copyright. All rights reserved
Considerations and recommendations

General considerations for patients with chronic pain and COVID-19 infection

Chronic pain, the immune response, opioid therapy and COVID-19

Pain and the immune system have a close relationship. Chronic pain exerts complex effects on the immune system, including immunosuppression in some individuals [17]. Immune cells and their products have a role in both inflammatory and neuropathic pain [18]. Significant immune system changes occur in patients with COVID-19 [19], with a higher risk of mortality observed in the elderly alongside individuals who have hypertension; diabetes; coronary artery disease; and chronic lung disease [20]. Although the mortality risk in cancer patients is unclear, early reports suggest a higher risk [21]. The association of comorbidities, old age and chronic pain increases the risk of immune suppression and subsequent COVID-19 infection. Opioids can have serious adverse effects including endocrine changes and the potential to suppress the immune system [22-24], however some suggest there could be beneficial effects [25]. Opioids can interfere with the innate and acquired immune response, act on the hypothalamic-pituitary-adrenal axis and the autonomic nervous system [23, 25, 26]. Higher doses and longer duration of therapy are associated with greater endocrine abnormalities [26]. Individual opioids differ in their effect on the immune system [27, 28], however morphine and fentanyl have been observed to be the most immunosuppressive [23, 29]. Based on available data, buprenorphine appears to be the safest to use in immunocompromised or elderly patients susceptible to infection [24]. The clinical relevance of these observations for individual opioids is unclear; however, observational studies indicate the potential for an increase in incidence and severity of infections in patients on opioids [30, 31]. It is therefore appropriate to consider that chronic pain patients on opioids could potentially be more susceptible to COVID-19 and other secondary infections. Furthermore, the potential for respiratory depression is higher in patients using fentanyl patches, as fever enhances absorption [32, 33].

Steroids in chronic pain and COVID-19

Chronic pain patients may take oral steroids or receive steroid injections for a wide variety of musculoskeletal conditions [34]. Patients who receive steroids have the potential for secondary adrenal
insufficiency and an altered immune response [35], along with several other adverse effects including myopathy and osteoporosis [36]. Among available steroids, the depot form of methylprednisolone is most frequently used for chronic pain. Secondary adrenal insufficiency with 80 mg methylprednisolone can last up to 4 weeks, however for a small proportion it could be up to 2 months [37]. Also, a recent trial evaluating epidural steroid injections noted that the duration of immune suppression could be less when using dexamethasone and betamethasone [38]. In a large retrospective study, the injection of corticosteroids into joints was shown to be associated with a higher risk of influenza [39]. Although the pathophysiology of COVID-19 infection suggests an exaggerated immune response, steroid use in COVID-19 patients is only recommended in those with refractory shock and this is based on low quality evidence [40]. During the 2003 SARS pandemic, arthralgias involving large joints were commonly observed during the recovery phase and many patients were treated with steroid therapy [41]. Those patients receiving higher doses and for longer treatment durations were more likely to develop osteonecrosis [42]. In view of these considerations, we feel that any new therapy that may influence the COVID-19 disease course should be discussed with the treating infectious disease physician. It should also be recognised that steroids are routinely used in many procedures despite an absence of evidence supporting the practice [43, 44]. The Faculty of Pain Medicine of the Royal College of Anaesthetists’ position statement urges caution on the safety of steroids injected during the current COVID-19 pandemic [45].

Psychological, physical, and social functions in chronic pain and COVID-19

The pain neuromatrix model integrates multiple inputs inclusive of: genetically informed synaptic architecture; sensory and/or afferent processing; cognitive; affective; motivational; immunoendocrine; and autonomic nervous system [46]. Chronic pain patients have higher prevalence of anxiety, depression, catastrophising, and suicidal ideation [47]. This may worsen during a period of crisis. Chronic pain patients also experience: social isolation; stigma; loss of personal identity; and financial stress. These all negatively impact on psychological health, social circumstances, and ongoing pain, which are likely further exacerbated during a pandemic. It is imperative these issues are addressed during a pandemic and this is best achieved by using a biopsychosocial model of pain management.

Therapeutic considerations and recommendations for chronic pain during the COVID-19 pandemic

A summary of therapeutic considerations and recommendations for chronic pain management during the COVID-19 pandemic is displayed in Table 1.
In-person visits

In-person visits during a pandemic expose patients and others to the risk of infection, hence all elective surgeries and procedures should be postponed or cancelled. Furthermore, conserving resources is important as health systems already strained by diminished production capacity, travel and shipping restrictions, must be prepared for further casualties. Whenever possible, telemedicine should be considered. However, there are certain clinical scenarios that necessitate in-person visits, including procedures. Categorising pain procedures as elective, urgent and emergent is, in many cases, subjective. The American College of Surgeons provides some direction, noting that both medical and logistical contexts must be considered on a case-by-case basis [48]. We provide examples of urgent and semi-urgent pain procedures later in these recommendations. It is important that, for planned visits, patients and personnel are screened for symptoms of COVID-19. Individuals with a high risk of having COVID-19 should potentially undergo diagnostic testing prior to in-person visits, if available as per local testing protocols, or be seen after symptoms subside. This needs to be undertaken, recognising the limited sensitivity of detecting infection from the presently available tests and the feasibility that a patient may have become infected after a previous negative test. Once the community spread of infection becomes significant, all cases may be presumed to be COVID-19 positive. Clinical settings must adhere to physical distancing recommendations and other regulations as noted by the local health authorities.

Telemedicine

Telehealth and telemedicine are related terms that define telecommunication and the electronic exchange of information through a variety of platforms. This includes such services as telehealth visits, virtual encounters, and e-visits. Randomised controlled trials have demonstrated high levels of: patient satisfaction; comfort; convenience; and acceptance for telehealth services including for patients requiring post-procedural follow-up and with chronic disease states [49, 50]. There is an enormous potential for cost reduction and time savings with telehealth services [50]. In any pandemic, it is important that physicians continue to provide medical services in a safe and effective way and telehealth can help meet these needs. Preliminary data exists regarding the effectiveness for psychotherapies delivered on internet-based platforms such as smartphone apps and whilst these may be beneficial during public health crises, there are recognised limitations such as a lack of culturally tailored information and testing in individuals with persistent pain [51]. For telemedicine, technology should be selected that is easy to use and maintains the confidentiality of personal health information.

This article is protected by copyright. All rights reserved
Healthcare providers must be aware of the licensure requirements in their area of practice and recognise that many of the waivers and alterations in regulations that have occurred during the COVID-19 pandemic will be reversed once the pandemic resolves. Therefore continuously monitoring these changes ensures practice remains compliant with privacy and data protection legislation. During the COVID-19 pandemic the US and the UK, under special billing provisions, have reduced or eliminated pre-existing barriers to telehealth including the requirement to use a Health Insurance Portability and Accountability Act compliant platform [52]. Similarly, in Canada, the provincial Ministries of Health have relaxed the regulations around the use of telemedicine. An example from the UK is the adoption of Microsoft Teams by NHS digital for roll-out to NHS staff in England and Wales to facilitate working from home and streamlining communication between patients and medical professionals. Microsoft Teams is currently being integrated by NHS digital into its security platform and was made available to all NHS email users from 20 March 2020 [53]. Whilst outside the scope of these recommendations, the review by Eccleston et al. outlines more details regarding considerations for rapid integration of remotely supported pain management services [16].

**Biopsychosocial management of pain**

It is imperative for patients with pain to have access to trained psychologists, physical therapists and social workers to address the psychological and physical impact of their pain and other co-morbidities. Social distancing precautions in response to this pandemic pose unique challenges for multidisciplinary care. However advances in telemedicine outlined above, including interactive audio-video platforms, provide an opportunity to comprehensively assess patients and deliver virtual biopsychosocial and physical care that can be supplemented with in-person consultations at a later stage. Multidisciplinary pain self-management programs and strategies for self-management of pain can and are being delivered online [54]. Individual studies report excellent outcomes [55] and a systematic review of internet interventions for chronic pain found that those based on cognitive behavioural therapy can be efficacious [56]. Examples of interventions that can be delivered effectively over the internet for patients with chronic pain include: managing stress; addressing sleep disturbances; teaching mindfulness practices; cognitive strategies; pacing activities; social support programs; simple physical exercises; and observing a healthy lifestyle.

**Opioid prescriptions**

This article is protected by copyright. All rights reserved
Guidelines on opioid prescribing already exist to help minimise the harm from their application in chronic pain management [57, 58]. Broadly these considerations include: the need to determine when to initiate or continue opioids for chronic pain; appropriate opioid selection, dosage, duration, follow-up and discontinuation; and assessment of risks and harms of opioid use. Ideally, changes to opioid prescriptions should be made only after in-person careful evaluation of ongoing treatment, which includes a history and physical examination. However during the current COVID-19 health emergency, physicians may not be able to adhere to such a practice. In view of this, many countries have made changes to their policy on controlled substances. Such temporary allowances include enabling pharmacists to: extend prescriptions for a limited period of time; act on a verbal order by a physician for refill of controlled substances; deliver prescriptions of controlled substances to patient’s homes or other locations of self-isolation; and permitting registered practitioners to prescribe opioids without an in-person medical evaluation as long as some necessary conditions are met [59, 60]. Although controlled substances may be provided without a direct in-person medical evaluation, it is still recommended that opioid safe prescribing procedures be performed including: assessing for adequate response; adverse events; aberrant behaviours; function; and quality of life improvements [61]. Pill counts can still be performed and informed consent obtained via video communication. Patients should continue to be educated on the risks and benefits of opioids, naloxone should be prescribed when appropriate and the review of medical history and medications that impact opioid prescribing should be continued. We must be cognisant that psychological stress may exacerbate pain leading to greater opioid requirements and that patients may use medically-prescribed opioids for non pain related conditions such as: anxiety; depression; and insomnia despite evidence that in the long-term they can worsen these conditions [62]. Therefore any significant, sustained increase in opioid dose requires an in-person evaluation.

**Anti-inflammatory drugs use for chronic pain**

A substantial number of chronic pain patients use non-steroidal anti-inflammatory drugs (NSAIDS) for their pain control [63]. Non-steroidal anti-inflammatory drugs exert their analgesic effect primarily through peripheral inhibition of prostaglandin synthesis by acting on the cyclo-oxygenase enzyme, although other peripheral and central mechanisms of analgesic action exist. There are two structurally distinct forms of the cyclo-oxygenase enzyme (COX-1 and COX-2) [64]. COX-1 is constitutively expressed in normal cells, while COX-2 is induced in inflammatory cells. One of the mechanisms underlying antihypertensive actions of angiotensin converting enzyme (ACE) inhibitors involves the kinin-prostaglandin system [65]. An observation by the current French health minister had initially prompted
some physicians to advise against the use of ibuprofen or other NSAIDS, based on the assumption that its use may increase the severity of COVID-19 disease [66]. This was based on the assumption that NSAIDS could increase the levels of ACE. However this has not been substantiated by other any reports and multiple regulatory bodies have since refuted this assertion [67-69]. However NSAIDS may mask early symptoms of the disease such as fever and myalgias.

Procedural precautions and considerations
For patients needing procedures, all considerations and recommendations mentioned above for inpatient visits are applicable. Several guidelines from various medical organisations have emphasised the importance of personal protective equipment (PPE) [15]. One must be also aware of local policies on precautions and equipment. Additional aspects related to procedural precautions that should be highlighted include the recommendation that all procedures should be carried out by an experienced person. These procedures do not lead to aerosol generation and therefore personal protective equipment that adheres to geographical recommendations for contact and droplet precautions is generally considered sufficient. Additional protection for consideration may be made on a case-to-case basis depending upon local availability. Furthermore any equipment such as the ultrasound machine and intrathecal (ITP) equipment or programmer, should be protected from contamination using an appropriate cover. In addition it is important to ensure that the needed medications (for example ITP refill) and equipment are ready and transported in a fully covered plastic bag, with the bag and its medications handled with sterile gloves in a clean area.

Examples of scenarios that represent “urgent” pain patient procedures during the COVID-19 pandemic include ITP refills or malfunction and neuromodulation infection or malfunction. ITP refills necessitate close proximity (< 1 metre) between the operator and patient. For patients on intrathecal baclofen, an abrupt reduction in gamma-aminobutyric acid agonist activity in the central nervous system following abrupt cessation of baclofen infusion can lead to a catastrophic intrathecal baclofen withdrawal syndrome [70]. This usually evolves over 1 to 3 days but may become fulminant if not recognised and treated promptly. The best management strategy is resuming the intrathecal infusion as soon as possible. Other supportive measures including high-dose benzodiazepine intravenous infusion or baclofen may be lifesaving before intrathecal baclofen therapy can be resumed, though acute withdrawal may still occur with high-dose oral baclofen [71]. Although clonidine is not currently approved as intrathecal therapy [72], it is often used in clinical practice and the Polyanalgesic Consensus
Conference panel recommendations for intrathecal drug delivery assign a grade B evidence for its use in neuropathic and nociceptive pain [73]. Intrathecal clonidine withdrawal can result in hypertensive crisis and cardiomyopathy [74]. It should be noted that there are no reported withdrawal symptoms when intrathecal ziconotide as a sole therapy was discontinued [73]. In general for all patients at high risk of intrathecal drug withdrawal should be identified and educated pre-emptively. Pain physicians should be familiar with the emergency treatment of intrathecal medication withdrawal symptoms and may need to consider higher drug concentrations for the period of the pandemic in order to reduce ITP refill visits.

Although the use of some highly concentrated intrathecal medications can be associated with granuloma formation (inflammatory mass) at the tip of the catheter, this usually occurs with long-term infusions and needs to be weighed against the risk of infection acquired as a result of repeated hospital and practice visits. For more details about the recommended doses and concentrations for different intrathecal medications, practitioners are encouraged to refer to the Polyanalgesic Consensus Conference recommendations [73].

Neuromodulator systems used to treat chronic pain often include an implanted power generator connected to a stimulating "lead" in the dorsal epidural or in the perineural space. Being elective procedures, new trials or implants must be avoided during pandemics. In patients who have recently undergone an implant procedure, any procedure-related complications should initially be evaluated over telemedicine. In cases of unwanted paraesthesias, patients can be asked to switch off the stimulation using the external remote controller and consider managing their pain with medications alongside other biopsychosocial strategies. However certain issues may require in-person evaluation and management and the need for these must be considered on a case-by-case basis, with shared decision-making. Examples of issues necessitating an in-person evaluation may include: suspected infection of the implanted power generator or lead; unintended loss or change of programming resulting in severe unmanageable pain; and the need for an MRI for an unrelated indication such as risk of stroke or brain injury. Depending on whether the infection is superficial or deep, device explant may be warranted and should be performed as soon as possible [73].

Although not urgent, some situations may warrant a careful evaluation of individual risks and benefits so that a patient may be considered for an in-patient visit. These circumstances meet the criteria of semi-urgent” pain patient visits or procedures during the COVID-19 pandemic. Decision making on such occasions should be based on factors such as: the acuteness of the condition; potential for significant morbidity without intervention; the need for additional resources (such as monitoring for ketamine
infusions); the likelihood of benefit; and the potential for the patient to use emergency services. Overall, the goals must be to avoid: deterioration of function; reliance on opioids; or emergency service visits that increase risk of exposure. Such procedural scenarios may include, but not limited to, the following: intractable cancer pain; acute herpes zoster or subacute, intractable post-herpetic neuralgia; acute herniated disc and/or worsening lumbar radiculopathy; intractable trigeminal neuralgia; early complex regional pain syndrome; acute cluster headaches and other intractable headache conditions; and other intractable medically resistant pain syndromes.

Conclusion
Chronic pain causes significant suffering, leading to a reduced quality of life. During the COVID-19 pandemic there is a risk of chronic pain patients failing to receive important treatment due to reallocation of resources and reduction in services, to both limit the spread of infection and to deal with saving lives of those infected. Chronic pain patients may also be at increased risk of COVID-19 due to multiple factors. Important considerations for healthcare professionals caring for those with chronic pain are to: ensure continuity of care and pain medications; utilisation of telemedicine; maintaining biopsychosocial management approach; evaluation and safe conduct of urgent and semi-urgent procedures to avoid morbidity in chronic pain patients; and the need to modify ongoing therapies to decrease COVID-19 risk. These recommendations have been developed to aid healthcare professionals and we acknowledge these are not guidelines. However with COVID-19 being a rapidly evolving situation they represent summaries of the best available evidence and expert opinion at this present time and may need adapting to local workplace policies.

Acknowledgements
HS is supported by the Canadian Anesthesia Research Foundation through the Career Scientist Award, 2018–2020. DP has consulted for Avanos, Boston Scientific, Medtronic, Nevro, and Esteve. He has received research support from Avanos, Medtronic, Nevro, Stimgenics, and Abbott. SE has received consulting fees from Mainstay Medical, Medtronic and Saluda Medical. His department has received research funding from The National Institute of Health Research (NIHR), Nevro and Medtronic. SC is supported by grants from MIRROR, U.S. Dept. of Defense, Uniformed Services University, and the National Institutes of Health. No other competing interests declared.
REFERENCES

1. Breivik H, Eisenberg E, O'Brien T. The individual and societal burden of chronic pain in Europe: the case for strategic prioritisation and action to improve knowledge and availability of appropriate care. *BMC Public Health* 2013; **13**: 1229.

2. Gaskin DJ, Richard P. The economic costs of pain in the United States. *Journal of Pain* 2012; **13**: 715-24.

3. Mills SEE, Nicolson KP, Smith BH. Chronic pain: a review of its epidemiology and associated factors in population-based studies. *British Journal of Anaesthesia* 2019; **123**: e273-e83.

4. Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. *Journal of Pain* 2015; **16**: 769-80.

5. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *European Journal of Pain* 2006; **10**: 287-333.

6. Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *British Medical Journal Open* 2016; **6**: e010364.

7. Fayaz A, Ayis S, Panesar SS, Langford RM, Donaldson LJ. Assessing the relationship between chronic pain and cardiovascular disease: A systematic review and meta-analysis. *Scandinavian Journal of Pain* 2016; **13**: 76-90.

8. Murray CJ, Atkinson C, Bhatta K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. *Journal of the American Medical Association* 2013; **310**: 591-608.

9. Parker L, Moran GM, Roberts LM, Calvert M, McCahon D. The burden of common chronic disease on health-related quality of life in an elderly community-dwelling population in the UK. *Family Practice* 2014; **31**: 557-63.

10. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012; **380**: 37-43.

11. Brennan F, Carr D, Cousins M. Access to pain management-still very much a human right. *Pain Medicine* 2016; **17**: 1785-9.

This article is protected by copyright. All rights reserved
12. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. *Lancet Oncology* 2009; 10: 865-71.

13. Webster F, Rice K, Bhattacharyya O, Katz J, Oosenbrug E, Upshur R. The mismeasurement of complexity: provider narratives of patients with complex needs in primary care settings. *International Journal for Equity in Health* 2019; 18: 107.

14. Bluthenthal RN, Simpson K, Ceasar RC, Zhao J, Wenger L, Kral AH. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. *Drug and Alcohol Dependence* 2020. Epub ahead of print 2 March. https://doi.org/10.1016/j.drugalcdep.2020.107932

15. ASRA. Recommendations on Chronic Pain Practice during the COVID-19 Pandemic. 2020. https://www.asra.com/page/2903/recommendations-on-chronic-pain-practice-during-the-covid-19-pandemic (accessed 31/03/2020).

16. Eccleston C, Blyth FM, Dear BF, et al. Managing patients with chronic pain during the Covid-19 outbreak: considerations for the rapid introduction of remotely supported (e-health) pain management services. *Pain* 2020. Epub ahead of print 2 April. 10.1097/j.pain.0000000000001885

17. Ren K, Dubner R. Interactions between the immune and nervous systems in pain. *Nature Medicine* 2010; 16: 1267-76.

18. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. *Nature Reviews Neuroscience* 2005; 6: 521-32.

19. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Military Medical Research* 2020; 7: 11.

20. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 39: 1054-62.

21. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncology* 2020; 21: 335-7.
22. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. *Annals of Internal Medicine* 2015; 162: 276-86.

23. Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. *Journal of Neuroimmunology* 1998; 83: 19-28.

24. Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). *Pain Practice* 2008; 8: 287-313.

25. Plein LM, Rittner HL. Opioids and the immune system - friend or foe. *British Journal of Pharmacology* 2018; 175: 2717-25.

26. Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. *Clinical Journal of Pain* 2010; 26: 374-80.

27. Franchi S, Moschetti G, Amodeo G, Sacerdote P. Do all opioid drugs share the same immunomodulatory properties? A review from animal and human studies. *Frontiers in Immunology* 2019; 10: 2914.

28. Sacerdote P. Opioids and the immune system. *Palliative Medicine* 2006; 20 (Suppl 1): s9-15.

29. Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats. Dose and timing study. *Neuroimmunomodulation* 2004; 11: 255-60.

30. Dublin S, Walker RL, Jackson ML, et al. Use of opioids or benzodiazepines and risk of pneumonia in older adults: a population-based case-control study. *Journal of the American Geriatrics Society* 2011; 59: 1899-907.

31. Wiese AD, Griffin MR, Stein CM, Mitchel EF, Jr., Grijalva CG. Opioid analgesics and the risk of serious infections among patients with rheumatoid arthritis: a self-controlled case series study. *Arthritis and Rheumatology* 2016; 68: 323-31.

This article is protected by copyright. All rights reserved
32. [No Authors Listed]. In brief: heat and transdermal fentanyl. *The Medical Letter on Drugs and Therapeutics* 2009; **51**: 64.

33. Herndon CM. Iontophoretic drug delivery system: focus on fentanyl. *Pharmacotherapy* 2007; **27**: 745-54.

34. Shanthanna H, Busse JW, Thabane L, et al. Local anesthetic injections with or without steroid for chronic non-cancer pain: a protocol for a systematic review and meta-analysis of randomized controlled trials. *Systematic reviews*. 2016; **5**:18.

35. Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative steroid management: Approaches based on current evidence. *Anesthesiology* 2017; **127**: 166-72.

36. Nah SY, Lee JH, Lee JH. Effects of epidural steroid injections on bone mineral density and bone turnover markers in patients taking anti-osteoporotic medications. *Pain Physician* 2018; **21**: E435-e47.

37. Habib G, Khazin F, Jabbour A, et al. Simultaneous bilateral knee injection of methylprednisolone acetate and the hypothalamic-pituitary adrenal axis: a single-blind case-control study. *Journal of Investigative Medicine* 2014; **62**: 621-6.

38. Friedly JL, Comstock BA, Heagerty PJ, et al. Systemic effects of epidural steroid injections for spinal stenosis. *Pain* 2018; **159**: 876-83.

39. Sytsma TT, Greenlund LK, Greenlund LS. Joint Corticosteroid Injection Associated With Increased Influenza Risk. *Mayo Clinic Proceedings Innovations, Quality And Outcomes*. 2018; **2**: 194-8.

40. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Medicine* 2020. Epub ahead of print 28 March. https://doi.org/10.1007/s00134-020-06022-5

41. Griffith JF. Musculoskeletal complications of severe acute respiratory syndrome. *Seminars in Musculoskeletal Radiology* 2011; **15**: 554-60.

42. Zhao R, Wang H, Wang X, Feng F. Steroid therapy and the risk of osteonecrosis in SARS patients: a dose-response meta-analysis. *Osteoporosis International* 2017; **28**: 1027-34.

43. Van Boxem K, Rijsdijk M, Hans G, et al. Safe use of epidural corticosteroid injections: recommendations of the WIP Benelux Work Group. *Pain Practice* 2019; **19**: 61-92.

This article is protected by copyright. All rights reserved
44. Shanthanna H, Wang L, Kaushal A, et al. The benefit of adding steroids to local anesthetics for chronic non-cancer pain interventions; a systematic review and meta-analysis of randomized controlled trials, 2018. https://www.asra.com/content/documents/6284_the-benefit-of-adding-steroids_1809220757.pdf (accessed 31/03/2020).

45. Faculty of Pain Medicine. FPM response to concern related to the safety of steroids injected as part of pain procedures during the current COVID-19 virus pandemic, 2020. https://fpm.ac.uk/sites/fpm/files/documents/2020-03/FPM-COVID-19-Steroid-Statement-2020-v2.pdf (accessed 31/03/2020).

46. Melzack R. Pain and the neuromatrix in the brain. Journal of Dental Education. 2001; 65: 1378-82.

47. Darnall BD, Carr DB, Schatman ME. Pain psychology and the biopsychosocial model of pain treatment: ethical imperatives and social responsibility. Pain Medicine 2017; 18: 1413-5.

48. American College of Surgeons. COVID-19: Guidance for Triage of Non-Emergent Surgical Procedures, 2020/ https://www.facs.org/about-acs/covid-19/information-for-surgeons/triage (accessed 31/03/2020).

49. Edwards L, Thomas C, Gregory A, et al. Are people with chronic diseases interested in using telehealth? A cross-sectional postal survey. Journal of Medical Internet Research 2014; 16: e123.

50. Soegaard Ballester JM, Scott MF, Owei L, Neylan C, Hanson CW, Morris JB. Patient preference for time-saving telehealth postoperative visits after routine surgery in an urban setting. Surgery 2018; 163: 672-9.

51. Devan H, Farmery D, Peebles L, Grainger R. Evaluation of self-management support functions in apps for people with persistent pain: systematic review. Journal of Medical Internet Research mHealth and uHealth 2019; 7: e13080.

52. US Department of Health and Human Services. Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency, 2020. https://www.hhs.gov/hipaa/for-professionals/special-topics/emergency-preparedness/notification-enforcement-discretion-telehealth/index.html (accessed 31/03/2020).
53. Porter S. NHS staff to receive free access to Microsoft Teams and Locum’s Nest. 
https://www.healthcareitnews.com/news/europe/nhs-staff-receive-free-access-microsoft-teams-and-locum-s-nest (accessed 31/03/2020).

54. Toronto Academic Pain Medicine Institute. Pain U Online. http://tapmipain.ca/patient/managing-my-pain/pain-u-online/#/ (accessed 02/04/2020).

55. Smith J, Faux SG, Gardner T, et al. Reboot online: a randomized controlled trial comparing an online multidisciplinary pain management program with usual care for chronic pain. Pain Medicine 2019; 20: 2385-96.

56. Buhrman M, Gordh T, Andersson G. Internet interventions for chronic pain including headache: a systematic review. Internet Interventions 2016; 4: 17-34.

57. Busse JW, Craige S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. Canadian Medical Association Journal 2017; 189: E659-e66.

58. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. Morbidity and Mortality Weekly Report. Recommendations and Reports 2016; 65: 1-49.

59. Health Canada. 
http://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/CDSA_exemption.pdf (accessed 31/03/2020).

60. US Department of Justice Drug Enforcement Administration. Diversion Control Division. COVID-19 Information Page. www.deadiversion.usdoj.gov/coronavirus.html (accessed 31/03/2020).

61. Provenzano DA, Viscusi ER. Rethinking the role of opioids in the outpatient management of chronic nonmalignant pain. Current Medical Research and Opinion 2014; 30: 2051-62.

62. Arteta J, Cobos B, Hu Y, Jordan K, Howard K. Evaluation of how depression and anxiety mediate the relationship between pain catastrophizing and prescription opioid misuse in a chronic pain population. Pain Medicine 2016; 17: 295-303.

63. Ho KY, Gwee KA, Cheng YK, Yoon KH, Hee HT, Omar AR. Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice. Journal of Pain Research 2018; 11: 1937-48.

This article is protected by copyright. All rights reserved
64. Cashman JN. The mechanisms of action of NSAIDs in analgesia. *Drugs* 1996; **52** (Suppl 5): 13-23.

65. Covi G, Minuz P, Capuzzo G, Lechi C, Delva P, Lechi A. Reduction of the antihypertensive effect of captopril induced by prostaglandin synthetase inhibition. *International Journal of Clinical Pharmacology Research.* 1984; **4**: 47-52.

66. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. *British Medical Journal* 2020; **368**: m1086.

67. British Medical Journal Best Practice. Coronavirus disease 2019 (COVID-19). https://bestpractice.bmj.com/topics/en-gb/3000168/treatment-algorithm#referencePop126) (accessed 31/03/2020).

68. Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19 (accessed 31/03/2020).

69. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19, 2020. https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19 (accessed 31/03/2020).

70. Gabay E, Tal M. Pain behavior and nerve electrophysiology in the CCI model of neuropathic pain. *Pain* 2004; **110**: 354-60.

71. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. *Archives of Physical Medicine and Rehabilitation* 2002; **83**: 735-41.

72. Food and Drug Administration Communication. Use Caution with Implanted Pumps for Intrathecal Administration of Medicines for Pain Management: FDA Safety Communication, 2018. https://www.fda.gov/medical-devices/safety-communications/use-caution-implanted-pumps-intrathecal-administration-medicines-pain-management-fda-safety (accessed 31/03/2020).

73. Deer TR, Provenzano DA, Hanes M, et al. The Neurostimulation Appropriateness Consensus Committee (NACC) recommendations for infection prevention and management. *Neuromodulation* 2017; **20**: 31-50.

This article is protected by copyright. All rights reserved
74. Lee HM, Ruggoo V, Graudins A. Intrathecal clonidine pump failure causing acute withdrawal syndrome with 'stress-induced' cardiomyopathy. *Journal of Medical Toxicology* 2016; 12: 134-8.

Table 1: Summary of therapeutic considerations and recommendations for chronic pain management during the COVID-19 pandemic

| In-patient visits                                                                 |                                                                 |
|----------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Any elective in-person patient visits or meetings should be suspended.          | No elective pain procedures should be performed, excepting specific semi-urgent procedures. |

**Use of telemedicine**

- Use telemedicine as the first approach and exclusively in most cases.
- Ensure adherence to the subscribed needs of telemedicine required by individual state or country of practice.

**Biopsychosocial management of pain**

- Telemedicine platforms are available to engage in multidisciplinary interactions.
- Whenever possible, online self-management programmes that integrate components of exercise, sleep hygiene, pacing and healthy lifestyle should be considered.
- Multi-disciplinary therapies could be helpful in overcoming increased opioids needs and/or procedures during the pandemic.

**Prescribing opioids**

- Use telemedicine to evaluate, initiate, and continue opioid prescriptions.
- Ensure all patients receive their appropriate prescription of opioids to avoid withdrawal.
- Naloxone education and prescription for high-risk patients.
- Inform patients of the risks and impact of long-term opioid therapy on the immune system.
- Communicate with other healthcare providers in the patients’ circle-of-care including family physicians, pharmacists and nurses.
Principles for using NSAIDS

- We recommend all patients prescribed or who use non-steroidal anti-inflammatory drugs on a regular basis to continue their use, whilst monitoring for adverse effects.
- We recommend educating patients on non-steroidal anti-inflammatory drugs that any mild fever or new myalgia should be promptly reported.

Intrathecal drug delivery systems

- Avoid insertion of any new ITP except for highly selected cancer pain cases where the benefit is considered to outweigh the risk. Consider proceeding straight to an implant, without a trial, for appropriate candidates.
- In COVID-19 suspected or symptomatic patients, consider the possibility of delaying the refill if the low reservoir alarm date allows a time frame until the patient has served a recommended self-isolation period.
- Following a thorough discussion with the patient, consider: the risk benefit balance of discontinuing ITP therapy in high risk patients on ziconotide therapy where no withdrawal effects have been reported; and the risk benefit ratio of using higher drug concentrations for the period of the pandemic in order to reduce ITP refill related visits.

Neurostimulator issues

- Avoid any new trials or implants.
- Use telemedicine as much as possible to resolve patient concerns. An audiovisual interview makes it easier to evaluate or troubleshoot most issues.

Principles for semi-urgent visits/procedures

- Comprehensive evaluation required and the need to help patients make informed decisions.
- Use telemedicine to evaluate the patient, triage the urgency, and make suitable arrangements for treatment. This will minimise delay and prevent unnecessary visits.

Figure 1: Chronic pain patient care during the COVID-19 pandemic
**Figure 1:** Flow chart summarizing chronic pain patient care during the COVID-19 pandemic